Author

T. Bruel

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 9 Microbiology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 15 Approach:experimental assay· 14 Organism:human· 11 Assay:proteomics· 7 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:mouse· 2

Frequent Co-Authors

O. Schwartz· 14 shared C. Planchais· 10 shared H. Mouquet· 10 shared D. Planas· 9 shared F. Porrot· 9 shared E. Simon-Loriere· 7 shared F. Guivel-Benhassine· 7 shared I. Staropoli· 7 shared

Activity by Year

2017-2023 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

14 shared papersImmunology

O. Schwartz

Mutual co-authors in cluster

Author profile →

16 papers

Recent·Most cited

Sex and species associated differences in Complement-mediated immunity in Humans and Rhesus macaques

N. S. Kelkar, B. S. Goldberg, J. Dufloo, T. Bruel, O. Schwartz, A. J. Hessell, M. E. Ackerman

This study compares complement-mediated immunity differences between humans and rhesus macaques, finding sex-based variations in humans and species-specific differences in complement activity.

bioRxiv · Oct 23, 2023Immunology

High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1

W. Bolland, V. Michel, D. Planas, M. Hubert, F. Guivel-Benhassine, F. Porrot, I. Staropoli, M. N'Debi, C. Rodriguez, S. Fourati, M. Prot, C. Planchais, L. Hocqueloux, E. Simon-Loriere, H. Mouquet, , J. Buchrieser

This study characterizes the high fusogenicity and cytopathic effects of the SARS-CoV-2 B.1.640.1 variant, identifying mutations in the spike S2 domain responsible for these properties.

bioRxiv · Sep 6, 2023Microbiology

Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity

R. Moirangthem, S. Cordela, D. Khateeb, M. Mandelboim, F. Jonsson, T. Bruel, Y. Bar-On

This study shows a bispecific antibody targeting both influenza virus hemagglutinin and neuraminidase improves antiviral activity by blocking infection and preventing virus release.

bioRxiv · Mar 16, 2023Immunology

Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies

D. Planas, T. Bruel, I. Staropoli, F. Guivel-Benhassine, F. Porrot, P. Maes, L. Grzelak, M. Prot, S. Mougari, C. Planchais, J. Puech, M. Saliba, R. Sahraoui, F. Femy, N. Morel, , O. Schwartz

This study evaluates the neutralizing antibody resistance of SARS-CoV-2 Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to monoclonal antibodies and sera from vaccinated individuals.

bioRxiv · Nov 17, 2022Microbiology

IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies

L. Grzelak, F. Roesch, A. Vaysse, A. Biton, F. Porrot, P.-H. Commere, C. Planchais, H. Mouquet, M. Vignuzzi, T. Bruel, O. Schwartz

This study identifies IRF8 as a regulator of CD20 expression and anti-CD20 antibody efficacy through CRISPR screening and functional validation in B cells.

bioRxiv · Jun 9, 2022Immunology

Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody

J. L. Torres, G. Ozorowski, E. Andreano, H. Liu, J. Copps, G. Piccini, L. Donnici, M. Conti, C. Planchais, D. Planas, N. Manganaro, E. Pantano, I. Paciello, P. Pileri, T. Bruel, , A. B. Ward

The paper evaluates the potency of mAb J08 against SARS-CoV-2 variants using cell-based assays and cryo-EM, showing its resistance to escape mutations and broad binding capability.

Proceedings of the National Academy of Sciences · May 12, 2022Peer-reviewedImmunology

Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2

C. Planchais, I. Fernandez, T. Bruel, G. Dias de Melo, M. Prot, M. Beretta, P. Guardado-Calvo, J. Dufloo, L. M. Molinos-Albert, M. Backovic, J. Chiaravalli, E. Giraud, B. Vesin, L. Conquet, L. Grzelak, , H. Mouquet

The paper identifies potent broadly neutralizing IgA and IgG antibodies against SARS-CoV-2 variants, including Omicron BA.1 and BA.2, from memory B cells in convalescents.

bioRxiv · Apr 1, 2022Immunology

Fusogenicity and neutralization sensitivity of the SARS-CoV-2 Delta sublineage AY.4.2

N. Saunders, D. Planas, W. H. Bolland, C. Rodriguez, S. Fourati, J. Buchrieser, C. Planchais, M. Prot, I. Staropoli, F. Guivel-Benhassine, F. Porrot, D. Veyer, H. Pere, N. Robillard, M. Saliba, , O. Schwartz

This study examines the fusogenicity and neutralization sensitivity of the SARS-CoV-2 AY.4.2 sublineage compared to the Delta variant, finding similar spike function but reduced neutralization sensitivity to certain antibodies and vaccines.

bioRxiv · Jan 7, 2022Microbiology

Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization

D. Planas, N. Saunders, P. Maes, F. G. Benhassine, C. Planchais, F. Porrot, I. Staropoli, F. Lemoine, H. Pere, D. Veyer, J. Puech, J. Rodary, W. H. Bolland, J. Buchrieser, G. Baele, , O. Schwartz

This study shows that the Omicron variant of SARS-CoV-2 is resistant to most monoclonal antibodies and vaccine-induced antibodies, with reduced neutralization compared to Delta.

bioRxiv · Dec 14, 2021Immunology

Robust and Functional Immunity up to 9 months after SARS-CoV-2 infection: a Southeast Asian longitudinal cohort

H. M. T. Vo, A. Maestri, S. Lay, S. Sann, N. Ya, L. Sovann, S. Sopheak, P. Pean, H. Auerswald, O. Schwartz, T. Bruel, S. Heng, P. Dussart, S. Ly, V. Duong, , T. Cantaert

The paper evaluates immune responses up to 9 months post-SARS-CoV-2 infection in a Cambodian cohort, showing sustained functional immunity without re-infection.

bioRxiv · Aug 12, 2021Immunology

Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals

D. Planas, D. Veyer, A. Baidaliuk, I. Staropoli, F. Guivel-Benhassine, M. Rajah, C. Planchais, F. Porrot, N. Robillard, J. Puech, M. Prot, F. Gallais, P. Gantner, A. Velay, J. Le Guen, , O. Schwartz

This study shows that the SARS-CoV-2 B.1.617.2 variant is less sensitive to monoclonal antibodies and sera from convalescent and vaccinated individuals compared to other variants.

bioRxiv · May 26, 2021 · PreprintMicrobiology

Identification of DAXX As A Restriction Factor Of SARS-CoV-2 Through A CRISPR/Cas9 Screen

A. Mac Kain, G. Maarifi, S.-M. Aicher, N. Arhel, A. Baidaliuk, S. Munier, F. Donati, T. Vallet, Q. D. Tran, A. Hardy, M. Chazal, F. Porrot, M. Ohainle, J. Carlson-Stevermer, J. Oki, , F. Roesch

The paper identifies DAXX as a restriction factor of SARS-CoV-2 through a CRISPR/Cas9 screen, showing it limits viral replication independently of SUMOylation.

bioRxiv · May 6, 2021Microbiology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

D. Planas, T. Bruel, L. Grzelak, F. Guivel-Benhassine, I. Staropoli, F. Porrot, C. Planchais, J. Buchrieser, M. M. Rajah, E. Bishop, M. Albert, F. Donati, S. Behillil, V. Enouf, M. Marianne, , O. Schwartz

This study assesses the neutralization sensitivity of SARS-CoV-2 B.1.1.7 and B.1.351 variants compared to D614G using sera and nasal swabs, finding reduced efficacy against B.1.351 in some convalescent and vaccinated individuals.

bioRxiv · Feb 12, 2021 · PreprintImmunology

Syncytia formation by SARS-CoV-2 infected cells

J. Buchrieser, J. Dufloo, M. Hubert, B. Monel, D. Planas, M. M. Rajah, C. Planchais, F. Porrot, F. Guivel-Benhassine, S. van der Werf, N. Casartelli, H. Mouquet, T. Bruel, O. Schwartz

This study shows SARS-CoV-2 infected cells form syncytia via Spike protein-mediated fusion, regulated by IFITMs and TMPRSS2.

The EMBO Journal · Nov 4, 2020Peer-reviewedMicrobiology

SARS-CoV-2 infection damages airway motile cilia and impairs mucociliary clearance

R. Robinot, M. Hubert, G. Dias de Melo, F. Lazarini, T. Bruel, N. Smith, S. Levallois, F. Larrous, J. Fernandes, S. Gellenoncourt, S. Rigaud, O. Gorgette, C. Thouvenot, C. Trebeau, G. Dumenil, , L. A. Chakrabarti

This study shows SARS-CoV-2 infection damages airway motile cilia and impairs mucociliary clearance, potentially facilitating viral spread to the deeper lung.

bioRxiv · Oct 6, 2020 · PreprintMicrobiology

Stage-specific ISG expression reveals functional convergence of type I and II IFNs in SIV infection

N. Echebli, N. Tchitchek, S. Dupuy, T. Bruel, C. Pereira Bittencourt Passaes, N. Bosquet, R. Le Grand, C. Bourgeois, B. Favier, R. Cheynier, O. Lambotte, B. Vaslin

The paper analyzes ISG expression in SIV-infected macaques to show that both type-I and type-II IFNs contribute to ISG upregulation, with type-II IFN persisting during chronic infection.

bioRxiv · Sep 22, 2017Immunology